Transitioning issues in adolescent to young adult hemophilia patients with inhibitors: An approach for a growing population

Blood Coagulation and Fibrinolysis

Volumn 21, Issue SUPPL. 1, 2010, Pages

  Young, Guy ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

hemophilia inhibitors; transition hemophilia treatment center

Indexed keywords

INHIBITOR; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULTHOOD; ADVERSE OUTCOME; ARTHROPATHY; FINANCIAL MANAGEMENT; HEMOPHILIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SOCIAL PSYCHOLOGY;

ADOLESCENT; AGE FACTORS; AGING; ANTIBODIES; DECISION MAKING; HEMOPHILIA A; HUMANS; YOUNG ADULT;

EID: 77957602541     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000388936.54741.38     Document Type: Review

References (11)

1. Berntorp E. Prophylactic therapy for haemophilia: early experience. Haemophilia 2003;9(suppl 1):5-9.
2. Young G. New approaches in the management of inhibitor patients. Acta Haematol 2006;115:172-179.
3. Gouw SC, van der Bom JG, van den Berg M. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007;109:4648-4654.
4. Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 2009;35:23-734.
5. Center for Disease Control and Prevention. UDC Summary Report. Available at: https://www2a.cdc.gov/ncbddd/htcweb/UDC-Report/UDC-view1.asp?para1= NATION¶2=OUTCOMEH¶3=&ScreenWidth=2560&ScreenHeight=1024. Accessed April 29, 2010.
6. Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006;107:46-51.
7. Evatt BL. The tragic history of AIDS in the hemophilia population, 982-1984. J Thromb Hemost 2006;4:2295-2301.
8. Acharya SS. Hemophilic joint disease: current perspectives and potential future strategies. Transfus Apher Sci 2008;38:49-55.
9. Kempton CL, White GC. How we treat a hemophilia A patient with a FVIII inhibitor. Blood 2009;113:11-17.
10. Gomperts ED, Astermark J, Gringeri A, Teitel J. From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia A patients with inhibitors. Blood Rev 2008;22(suppl 1):S1-S11.
11. Soucie JM, Nuss R, Evatt B, Abdelhak A, Cowan L, Hill H, et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000;96:437-442.